Immune Spatial Differences Between Short and Long-term Surviving Glioblastoma Patients

Immune Spatial Differences Between Short and Long-term Surviving Glioblastoma Patients

Automated multiplex immunofluorescence workflow to interrogate the cellular composition of the tumor microenvironment

Automated multiplex immunofluorescence workflow to interrogate the cellular composition of the tumor microenvironment

Automated multiplex immunofluorescence enables single cell analysis of tumor stroma

Automated multiplex immunofluorescence enables single cell analysis of tumor stroma

Automation of Proximity Ligation Immunoassay for interaction between PD-L1 and PD-1 detection in the tumor microenvironment using microfluidic-based systems

Automation of Proximity Ligation Immunoassay for interaction between PD-L1 and PD-1 detection in the tumor microenvironment using microfluidic-based systems

Validation of a novel multiplex immuno-fluorescence panel for the spatial analysis of the tumor microenvironment

Validation of a novel multiplex immuno-fluorescence panel for the spatial analysis of the tumor microenvironment

Characterization of tumor budding and the tumor microenvironment in colorectal cancer using hyperplex immunofluorescence

Characterization of tumor budding and the tumor microenvironment in colorectal cancer using hyperplex immunofluorescence

Fully automated spatial multi-omics to map the tumor microenvironment with single-cell resolution

Fully automated spatial multi-omics to map the tumor microenvironment with single-cell resolution

Mapping the tissue composition with hyperplex immunofluorescence on delicate samples

Mapping the tissue composition with hyperplex immunofluorescence on delicate samples

Mapping the tumor microenvironment with sequential immunofluorescence, an automated image analysis pipeline, and spatial metrics

Mapping the tumor microenvironment with sequential immunofluorescence, an automated image analysis pipeline, and spatial metrics

Development of a multiplex test for predicting response to combined immunotherapies in patients with metastatic melanoma

Development of a multiplex test for predicting response to combined immunotherapies in patients with metastatic melanoma